CI-581a
Phase 2Small molecule
CI-581a is one of 6 small molecule programs targeting Depressive Symptoms. It is currently in Phase 2.
1
Indications
6
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Depressive Symptoms
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 2
AXS-05
AAxsome Therapeutics, Inc.
Phase 3
Psilocybin
COMPASS PathwaysPhase 1
CI-581a
NNew York State Psychiatric Institute
Phase 2
Ci-581b
NNew York State Psychiatric Institute
Phase 2
Hypoxia
UUniversity of Aarhus
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cocaine Use Disorder1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CI-581a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details